undamentalytics Newsletter
Sign in

Nurix Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Nurix Therapeutics, Inc. had total assets of $688m, total liabilities of $149m and shareholders' equity of $539m. It held $247m in cash against $0 of debt: net cash of $247m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Nov 20192020Nov 20202021Nov 20212022Nov 20222023Nov 20232024Nov 20242025Nov 2025LTMAug 2026
Cash and equivalents35119816455110247720
Receivables——60—0020
Total current assets392983113182966196071,104
Total assets443964774173566696881,195
Accounts payable23756111133
Deferred revenue (current)103341384838189
Total current liabilities16456671879686131
Total debt00000000
Total liabilities54106134113155142149227
Shareholders' equity−58290342304200527539968
Non-controlling interests and other (assets − liabilities − equity)48———————
Net debt (negative = net cash)−35−119−81−64−55−110−247−720
Shares outstanding18m—45m47m49m76m102m109m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NRIX vs RAREARWR vs NRIXMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nurix Therapeutics, Inc.